85-1563-01　Sorafenib, Free Base (BAY-43-9006, N-(phenyl]amino)-carboxamide, Nexavar) 5g　CAS No:284461-73-0　S5343-01

特徴

• Sorafenib (Bay 43-9006) is a novel bi-aryl urea compound that inhibits cell proliferation by targeting the ERK pathway and angiogenesis by targeting the receptor tyrosine kinases VEGFR-2 and PDGFR-b and their associated signaling cascades. Although sorafenib was initially developed as a Raf kinase inhibitor (IC50=6nM), it has since been shown to have activity against many receptor tyrosine kinases involved in tumorigenesis and angiogenesis including FGFR-1, wt BRAF and V599E mutant BRAF, as well as members of the so-called "split kinase" family: VEGFR-2, VEGFR-3, PDGFR-b, c-KIT, and Flt3. However, sorafenib is not active against erbB1, erbB2, ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-MET, c-yes, PKB, PKA, cdk1/cyclinB, PKC, and pim-1. In cellular mechanistic assays, sorafenib decreased basal phosphorylation of the ERK pathway in melanoma, breast, colon, and pancreatic tumor cell lines.
• Appearance:Supplied as an off-white powder.
• Purity:HPLC: ≥99%TLC: ≥99%
• Solubility:Soluble in DMSO at 200mg/ml; soluble in ethanol at 3.3mg/ml with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50uM; buffers, serum, or other additives may increase or decrease the aqueous solubility.
• Melting Point:204-206.5°C
• Elemental Anaylsis:Calculated:C=54.26%H=3.47%Cl=7.63%F=12.26%N=12.05%
• Storage and Stability:May be stored at RT for short-term only. Long-term storage is recommended at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.